|
New Frontiers in the
Treatment and Management of Alzheimer's Disease (AD):
What Managed
Care Needs to Know about New and Emerging Therapies
A continuing medical
education activity sponsored by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
the management of Alzheimer's Disease (AD)
These are archives of live webinars held between November 12 to
November 18, 2020.
If you participated in any of the live webinars, you are not
eligible to
claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all 3 or in order.
These activities are valid from December 15, 2020 to December 1,
2022
This
series is supported by an educational grant from Biogen
Audience:
This activity is intended for healthcare professionals practicing in managed
care environments.
Instructions for CME/NCPD: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
certificate.
Description:
Alzheimer’s disease is the most common form of
dementia, affecting an estimated 5 million people in the United States. It is a
cognitive disorder that includes behavioral impairment that interferes with
social and occupational functioning. Alzheimer’s disease care costs $172 billion
annually in the US alone. Fortunately for patients with Alzheimer's disease, new
and emerging therapies, including anti-beta-amyloid (Aß) monoclonal antibodies,
are undergoing late stage clinical trials or have been submitted for regulatory
review. This program will provide strategies to overcome challenges in the
optimal treatment and management of Alzheimer’s disease and highlight the role
of managed care professionals in making informed decisions on these new and
emerging therapies that will improve quality of life, significantly reduce
clinical decline, and minimize costs throughout the healthcare system. |
|
Benefit Design and Coordinated Care in Alzheimer’s Disease (AD):
What Managed Care Needs to Know about Emerging Therapies and
Reducing Clinical Decline
- Analyze the economic burden of Alzheimer’s disease (AD) and the impact
of suboptimal management on outcomes
- Review the latest clinical data on novel and emerging therapies,
including monoclonal antibodies, in the management of patients with
alzheimer"s disease (AD)
- Characterize the role of managed care professionals in supporting
appropriate utilization and administration of emerging therapies for AD
- Develop formulary positioning and benefit design strategies for emerging
AD therapies that encourage appropriate utilization while facilitating
patient access and adherence
- Assess the managed care considerations of new and emerging therapies,
including monoclonal antibodies, by exploring where these agents fit in the
AD management paradigm
- Identify practices that managed care professionals can use both now and
in the future to help improve outcomes, reduce clinical decline and ensure
appropriate and timely access to emerging therapies in AD
Physician, Nursing and CMCN credits valid to
December 1, 2022 |
|
Improving Patient Adherence and Quality of Life in Alzheimer’s
Disease (AD): Optimizing Adverse Event Management and Imaging
for Emerging Therapies
- Examine challenges to patient adherence, administration and quality of
life in the management of alzheimer’s disease (AD)
- Discuss strategies to implement emerging therapies, including monoclonal
antibodies, into the treatment paradigm, especially as it relates to patient
adherence and quality of life
- Evaluate adverse events associated with emerging therapies and
strategies to mitigate and manage these predictable toxicities that have
been reported in clinical trials
- Explore the role of neuroimaging in the diagnosis of AD, confirmation of
beta-amyloid deposition, monitoring of disease progression, and monitoring
of ARIA associated with investigative anti-β amyloid monoclonal antibody
therapies for maintaining patient adherence and QoL
- Identify practices that managed care professionals can use both now and
in the future to help improve outcomes, reduce clinical decline and ensure
appropriate and timely access to emerging therapies in AD
Physician, Nursing and CMCN credits valid to
December 1, 2022 |